Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Genfit is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Genfit employs 122 staff and has a trailing 12-month revenue of around $94.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $4.04 |
|---|---|
| 52-week range | $3.01 - $6.38 |
| 50-day moving average | $4.29 |
| 200-day moving average | $4.02 |
| Wall St. target price | N/A |
| PE ratio | 3.4545 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.10 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.04 from 2022-10-04
| 1 week (2022-09-28) | 1.51% |
|---|---|
| 1 month (2022-09-02) | -8.18% |
| 3 months (2022-07-05) | 20.24% |
| 6 months (2022-04-05) | 5.90% |
| 1 year (2021-10-05) | 7.73% |
|---|---|
| 2 years (2020-10-05) | -11.01% |
| 3 years (2019-10-04) | 14.45 |
| 5 years (2017-10-01) | N/A |
Valuing Genfit stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genfit's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genfit's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Genfit shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genfit's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $47.5 million.
The EBITDA is a measure of a Genfit's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $94.2 million |
|---|---|
| Operating margin TTM | 48.2% |
| Gross profit TTM | $85.6 million |
| Return on assets TTM | 15.32% |
| Return on equity TTM | 67.45% |
| Profit margin | 50.72% |
| Book value | $2.20 |
| Market capitalisation | $192.3 million |
TTM: trailing 12 months
We're not expecting Genfit to pay a dividend over the next 12 months.
Over the last 12 months, Genfit's shares have ranged in value from as little as $3.01 up to $6.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.2811. This would suggest that Genfit's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genfit S. A. , a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Here are the best renewable energy stocks that should be on your radar to help you grow your green portfolio
Here are 6 manganese stocks that should be on your radar as EV batteries create new demand.
Our list of 10 dividend stocks to watch in 2022.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.